Munch-a-Biotech Today Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: sim1	6/1/2010 1:20:20 AM
	of 3158

Top five oncology takeover targets for 2010 - analysis By Sasha Damouni and Nadia Damouni [FT] Published: May 31 2010 21:14 \| Last updated: May 31 2010 21:14 This article is provided to FT.com readers by Pharmawire—a news service focused on providing insight into the most price sensitive issues in the global pharmaceutical market. www.pharmawire.com ---------------------------------------------------------------- As oncology assets continue to be snatched up, several deal-making sources interviewed by Pharmawire have formulated a list of the top five M&A targets. Seattle Genetics (NASDAQ:SGEN) Allos (NASDAQ:ALTH) Abraxis BioScience (NASDAQ:ABII) Genzyme (NASDAQ:GENZ) Oncology Assets Dendreon (NASDAQ:DNDN) ---------------------------------------------------------------- Article: ft.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next